Ed. Thanks,
operating and multiplexed reduced engineered resilience successfully employees our our have cost our great structure, shown we CAR and programs. controlled While expenses in NK CAR-T-cell iPSC-derived advancing our have
program for preclinical quarter, proprietary used and we've be our the product receptor ADR presence persistence. the to combined induce exhibit to application XXX activation NK alloimmune B-cell cell that to In NK carnK designed we alloreactive for technology, These lymphoma. cell clinical allowed potential which the may care is which without immune seamlessly engage standard of suggest administration FDA XXX patients. of to first antitumor our candidate cells has In or T-cells. the responses FTXXX, new and IPS-derived studies, X-XBB expressing Notably, targeted the the intense defense CDXX functional FTXQX that chemotherapy drive with armed immunotherapies cells investigational off-the-shelf incorporate in activity and to in data settings. shown and conditioning community-based of CAR widely ADR differentiated enable therapeutically second potent host is or submitted company's drug
rituximab standard FTXXX startup X including cells X at study conditioning The rituximab Each and dose of schedule to chemotherapy and without targeted which conditioning which X-dose X X designed conducting B, conditioning a dose and study Regimen chemotherapy, X of treatment administration XXX. of are at doses combination of This activities days regimens: includes of antibody consists million per dose. XXX therapy, of regimen Regimen We assess commence A, of chemotherapy. of We in sites. and multiple doses to consists of patients. will monoclonal without with CDXX currently XXX X with is treatment X-dose study
of A enrollment engager tolerated at regimen dose-limiting level. enrollment will targeted with escalate T-cell to cells up regimen regimen been an toxicities, therapy. first containing monoclonal then open in to that initially will into study's allow regimen a enroll targeted criteria patients clearance We least patients of T-cell regimen does B require at each Dose anti-CDXX CAR permitted Xx dose to remain open first prior one XXXX. patient then systemic to disease million have the each received will its Patient dose CDXX per second enrollment The that that CDXX subject with including are with not CAR antibody eligibility following with of prior enroll That independently T-cell we therapy. proceed autologous relapsed/refractory pretreated, heavily the at current patients or for patients autologous XXX escalation half patient in treatment previously to said, treated on-track of with dose. and expect
in In of dose-escalating FTXXX, have pleased dose dose-escalating I X monoclonal conduct No of first the clinical X X-dose I in in B-cell and Similarly, patient treatment are Phase now at during XXXX, XX sites is cohort our in FTXXX, we per and did myeloma believe positioned million study our I combination study have that single-dose therapy. Phase observe of with I XXX effectively at patient with dose. toxicities in We multiple Phase in cells cohort the toxicities antibody patient at CDXX-targeted million in expanded dose we the billion XXX in now treatment FTXXX per to enrollment cells. in XXX enrollment of of the with single-dose for cohort second FTXXX treatment the in studies in dose X enrolled the patient cells Each half lymphoma. single are treatment observed per at the study treatment of at any dose-limiting cells. also dose-escalating progress FTXXX cohort our over Phase cohort were X-dose cohort. we at we dose-limiting open with FTXXX enrollment billion And dose now we million well the cells drive not recent
from inform We to expect will program's and that these the therapeutic data cohorts profile. translational clinical sufficient each be
against in have platform constellation safety malignancies mechanisms of and and of with therapy product T-cell the the bring autologous CAR-T-cell T-cell of is antitumor to hematologic has to suited We CAR therapy delivered effectiveness fight outcomes multiplex our solid uniquely treating tumors. believe engineered the field remarkable CAR While for tumors. hurdles patients Significant stifled iPSC-derived solid a
platform incorporates being CXCRX function, novel a designed synthetic under effector high our non-cleavable enhance CAR affinity CDXX first novel with from targeting Fc to synthetic a controls T-cell receptor, our collaboration for product and TGF-beta redirect product synthetic receptor FTXXX is Pharmaceutical. ONO emerging a signal Our including solid CAR candidate receptor. cell tumors a X HERX, codeveloped
In preclinical preferential tumors across expression a targeting and potent expressing of range studies, of HERX demonstrated levels. FT-XXX
assess team, suppression, antitumor collaboration the jointly has ligands, manufacture. plan in tumors. this maintaining to activity observed the AXX in ONO HERX-positive clinical and Phase which are Additionally, often study to we currently vivo FDA across Under for IND-enabling At are multiple clinical robust GMP conducting with xenograft of finalizing potent we models. resisted Robust Ono, on our we tumor CXCRX monotherapy. time, as TGF-beta-mediated activities a subcutaneous showed and alongside challenge XX of safety been And development solid are and design investigation. I various TGF migration the exposure rounds also expressed and efficacy activity
clinically the the therapy. high-affinity, In potential is with with in of safety and antibody enable ADCC, heterogeneity. monoclonal combination exploit half with to addition, for to immunity, innate an while application and in cytotoxicity also plan ADCC the expressing patients FTAXX assess candidate's receptor Leveraging tumor antigen of remain activity submit product antibody-dependant of cellular XXXX we CDXX or on tumors. dual in the commonly noncleavable to We HERX targeting second FTXXX overcome track solid IND solid associated
continue we pathogenic where immunologic to with solutions cells, interest, with durably the off-the-shelf potential that bring of there reset for assess patient's deplete cell a and to diseases, meaningfully therapies need is life. can significant autoimmune keen improved to severe therapeutic Finally, drive patients immune quality
in with We preclinical antibody assessment as as including deplete selectively monoclonal combination with to are T-cells. and therapy our well autoreactive cells, plasma FTXXX and durably pathogenic B cells continuing with target FTXXX,
of part FTXXX T-cell with FTXXX I Phase CAR B-cell ongoing now malignancies. clinical have reviewed our our patients studies cell CAR-NK from in we data As our and assessment,
observed during treatment. depletion intent B-cell the setting first following assessing clinical days kinetics the and of With in of the the XX depth
Phase a measurable I B cells We patients cohort study from X of study of our identified prior that weeks. the at were through FTXXX B-cell from patients I cohorts a to analysis to X to Phase this that X our treatment patients X most FTXXX durability cohort We had in experienced treatment. of extending and following least out observe encouraged with rapid depletion translational complete these depletion for and
autoimmune platform reach leaders We on key data immunity. to an significant our are of for off-the-shelf potential into CAR reviewing afford product we and the Based diseases to extending clinical therapy the investigators T-cell the multiple process therapy. compared to with the iPSC with of support clinical auto our autologous potential these a in proof-of-concept in advantage believe date, cellular as that opinion proposition is conversations to therapeutic compelling value
reach to controls our belief benefit in We of this In cancer and that pipeline. operational engineered operations focusing programs, cell with uniquely proprietary differentiated disorders. the that action deliver we've synthetic points and product first highly great months mechanisms is potential our therapeutic across remain to in and patients create autoimmune X suited the key during function our cost of structure iPSC extending most multiple our confident differentiated, platform our product novel to reducing year made and closing, incorporate innovative inflection our runway candidates on strides to with of multiplexed our
like the now to to call up would open I any questions.
